Tempus Announces the Appointment of Nobel Laureate and CRISPR Co-Inventor, Dr. Jennifer Doudna, to its Board of Directors

NEWS

February 11, 2021

Tempus, a leader in artificial intelligence and precision medicine, today announced that Dr. Jennifer Doudna has joined its Board of Directors. Dr. Doudna will serve as an advisor to Tempus and its leadership team, leveraging her vast experience in genomics innovation and research to support Tempus as it leads the way in applying AI and its unparalleled library of multi-modal data to personalize patient care.

Dr. Doudna is the Li Ka Shing Chancellor’s Chair and a Professor in the Departments of Chemistry and of Molecular and Cell Biology at the University of California, Berkeley. Her groundbreaking development of CRISPRCas9 as a genome-engineering technology, with collaborator Emmanuelle Charpentier, earned the two the 2020 Nobel Prize in Chemistry and forever changed the course of human and agricultural genomics research. 

Dr. Doudna is also the founder and President of the Innovative Genomics Institute, and a member of the Howard Hughes Medical Institute, Lawrence Berkeley National Lab, Gladstone Institutes, the National Academy of Sciences, and the American Academy of Arts and Sciences. She is a leader in the global public debate on the responsible use of CRISPR and has co-founded and serves on the advisory panel of several companies that use the technology in unique ways. 

“Jennifer is a pioneer in her field, and her work is an invaluable step forward in our collective effort to advance precision medicine,” said Eric Lefkofsky, Founder and CEO of Tempus. “We are honored to have her join our board, not only for her extensive knowledge and expertise, but also her vision for the role of gene editing to improve patient outcomes.”

“I look forward to working with the Tempus team as they continue to apply technology and artificial intelligence to healthcare, deploying intelligent diagnostics that enhance research, empower physicians, and positively change the lives of patients,” said Dr. Doudna.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.